Getting foreign genetic material into primary T cells is one of the more frustrating tasks in cell biology, and the protocols that work well for other cell types tend to fail here. T cells resist conventional transfection methods due to their small size, minimal cytoplasm, and active innate immune surveillance against foreign nucleic acids. The field has converged on electroporation as the dominant non-viral approach, but the details of how you set it up, what cargo you deliver, and how you handle cells afterward make the difference between a failed experiment and one that yields functional, edited T cells.
Why T Cells Are So Difficult to Transfect
Most chemical transfection reagents that work in adherent cell lines perform poorly in primary T lymphocytes. Lipid-based reagents, calcium phosphate, and cationic polymers all struggle because T cells are suspension cells with limited endocytic activity and a biology tuned to detect and respond to foreign nucleic acids. Researchers have long recognized that non-viral gene delivery into primary human T cells remains a major challenge, with conventional methods yielding low efficiency and high toxicity.1PubMed Central. The challenging nature of primary T lymphocytes for transfection: Effect of protamine sulfate on the transfection efficiency of chemical transfection reagents Part of the problem is biological: when T cells detect cytoplasmic DNA, they mount an innate immune response through the cGAS-STING pathway, which senses double-stranded DNA and triggers interferon signaling, inflammation, and cell death.2PubMed. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway This means the cell is actively working against you when you try to introduce plasmid DNA. The expression levels of key sensors like STING and IFI16 are inversely correlated with transfection efficiency across multiple cell types and delivery methods.3Molecular Therapy Nucleic Acids. Transcriptomic analysis of innate immune responses to plasmid DNA transfection in hard-to-transfect cells
Electroporation as the Standard Non-Viral Method
Electroporation uses brief electrical pulses to create temporary pores in the cell membrane, allowing nucleic acids or protein complexes to enter the cytoplasm. It remains the workhorse for non-viral T cell transfection because it bypasses the endosomal pathway entirely, delivering cargo directly into the cell interior. The catch is that the same electrical force that opens the membrane also damages cells, so every protocol is a negotiation between efficiency and viability.
The key variables are voltage, pulse duration, and pulse waveform. For DNA electroporation, one systematic optimization found that live cell counts decreased linearly as voltage climbed from 350 V to 550 V, but transfection efficiency peaked at 500 V. Above that, cell damage overtook any gains in delivery.4PubMed Central. Optimized DNA electroporation for primary human T cell engineering The parameters change substantially when you switch to mRNA as your cargo. For mRNA delivery into CD8+ T cells, a single square-wave pulse of 2 milliseconds at 200 to 220 V achieved over 81% transfection efficiency with 91% viability, numbers that would be hard to reach with DNA at any voltage.5Bio-Rad Application Notes. Optimizing Electroporation Conditions for High-Efficiency mRNA Transfection of CD8+ T Cells with the Gene Pulser Xcell Electroporation System
Choosing Your Cargo: mRNA Versus DNA
The choice between mRNA and DNA profoundly shapes every downstream decision in the protocol. mRNA enters the cytoplasm and gets translated immediately without needing to reach the nucleus. That means faster onset of expression, often detectable within 30 minutes of electroporation, and much lower toxicity because the cell’s DNA-sensing machinery is less aggressively triggered. In one well-characterized system, RNA electroporation produced 93% GFP expression in stimulated T cells with 82% viability, and expression peaked between 24 and 72 hours before declining to background by about two weeks.6Molecular Therapy. High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation Critically, the electroporated T cells showed no adverse effects on cell growth, apoptosis rates, or their ability to recognize target cells through engineered T cell receptors.
DNA, by contrast, must cross both the cell membrane and the nuclear envelope, and its presence in the cytoplasm triggers cGAS-STING-mediated toxicity. The tradeoff is that DNA can integrate into the genome (with appropriate tools), providing permanent transgene expression. For experiments that need only transient expression, such as screening guide RNAs, testing receptor constructs, or redirecting T cell specificity for a short therapeutic window, mRNA is almost always the better choice. For permanent modification, you either need a viral vector or a non-viral integration system paired with DNA.
A comparison in porcine T cells illustrates the gap: mRNA nucleofection achieved over 50% transgene expression with 62% viability in resting T cells, while optimized plasmid DNA nucleofection reached about 40% expression with 51% viability under the best conditions.7PubMed. High transfection efficiency of porcine peripheral blood T cells via nucleofection Both approaches left T cell function intact, with normal upregulation of activation markers and proliferation after stimulation.
CRISPR-Cas9 Delivery via Ribonucleoproteins
For genome editing, the field has largely moved toward delivering Cas9 as a pre-assembled ribonucleoprotein complex (the Cas9 protein already bound to its guide RNA) rather than as plasmid DNA encoding the components. This avoids the DNA-toxicity problem altogether. Cas9 RNPs electroporated into primary T cells can achieve near-complete loss of target gene expression at the population level, without requiring TCR stimulation beforehand and without needing to select edited cells afterward.8PubMed Central. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells A detailed step-by-step protocol for this approach has been published for both mouse and human T cells.9PubMed. Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells
RNP electroporation was demonstrated early on for clinically relevant targets. Cas9 RNPs directed against CXCR4, a co-receptor for HIV entry, caused roughly 40% of CD4+ T cells to lose cell-surface CXCR4 expression, and the edited population could be enriched by sorting.10PubMed Central. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins The RNP approach works for knockouts. For knock-ins, where you want to insert new sequence at the cut site, you need to combine it with a donor template.
Knock-In Protocols and HDR Templates
Knocking out a gene is relatively straightforward: deliver the RNP, let the cell’s error-prone repair pathway scramble the target sequence, and you are done. Knocking in a new sequence, such as a chimeric antigen receptor (CAR) cassette at a specific genomic locus, is harder because it requires the cell to use its homology-directed repair pathway, which is less active in T cells than the error-prone alternative.
The most successful non-viral knock-in protocols combine Cas9 RNP electroporation with an adeno-associated virus serotype 6 (AAV6) donor vector added immediately after electroporation at high multiplicity, typically thousands of viral genomes per cell. The AAV6-containing medium is removed after 24 hours.11Nucleic Acids Research. Dynamics and competition of CRISPR–Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing This hybrid approach (non-viral nuclease, viral template) has proven effective across multiple gene-editing platforms. In a head-to-head comparison using TALEN, CRISPR-Cas9, and CRISPR-Cas12a nucleases paired with AAV6 HDR templates, over 45% of patient-derived T cells showed targeted insertion of a therapeutic gene.12Frontiers in Genome Editing. Genome Editing With TALEN, CRISPR-Cas9 and CRISPR-Cas12a in Combination With AAV6 Homology Donor Restores T Cell Function for XLP
Transposon Systems for Stable Non-Viral Integration
If you want permanent transgene expression but prefer to avoid lentiviruses entirely, transposon systems offer a middle path. Sleeping Beauty and PiggyBac transposons can be delivered as plasmid DNA via electroporation, where the transposase enzyme cuts the transgene from the plasmid and pastes it into the genome at semi-random sites.
Sleeping Beauty-based CAR T cells have been generated by electroporating peripheral blood mononuclear cells with transposon plasmid, followed by expansion on feeder cells. While electroporation initially decreased viability on day one, it had only a minor impact on the frequency of memory T cell subpopulations, and the system produced long-term CAR expression.13PubMed. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo Protocols using the Lonza Nucleofector II device have been published in detail for this approach.14PubMed. Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System
PiggyBac transposon-generated CAR T cells behave differently from their lentiviral counterparts. A transcriptomic comparison found that PiggyBac CAR T cells had higher CAR expression in a subset of cells, greater upregulation of cytokines and chemokines, and faster in vitro killing of target cells, though in vivo anti-tumor activity was similar between the two manufacturing methods.15PubMed Central. Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection One intriguing finding was that PiggyBac CAR T cells expressed fewer cytokines associated with cytokine release syndrome, a dangerous side effect of CAR T therapy. Whether that translates into a clinical safety advantage remains to be seen.
How T Cell Activation State and Subset Affect Results
T cells exist in different functional states, and those states matter for transfection. Resting (unstimulated) T cells and activated T cells require different electroporation parameters, and different T cell subsets respond differently to the same protocol. Among the subsets, central memory T cells consistently show the highest transfection efficiency, which tracks with their greater proliferative capacity.16bioRxiv. Electroporation characteristics of human primary T cells
The choice of subset also affects what you can do with the transfected cells. When T cells were redirected with tumor-specific T cell receptors via RNA electroporation, memory-derived T cells showed much stronger cytolytic activity and maintained their acquired function for 5 to 10 days, compared to naive-derived T cells. The same approach worked for CD4+ T cells, turning them into potent antigen-specific helper cells. The conclusion from this work is that memory rather than naive T cells are the preferred starting population for transient TCR expression by RNA electroporation.17PubMed. Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy
For many CRISPR RNP protocols, the advantage is that you can edit T cells without prior TCR stimulation at all, preserving a less-differentiated phenotype that may be preferable for therapeutic applications where you want cells that persist long-term after infusion.
Recovery Medium and Buffer Optimization
What happens in the minutes and hours after electroporation matters as much as the pulse itself. The recovery medium can make or break an experiment. A systematic comparison of five different recovery media for mouse cytotoxic T lymphocytes and two for human cells found that a custom formulation based on Opti-MEM-GlutaMAX supplemented with HEPES, DMSO, and sodium pyruvate outperformed the manufacturer’s standard recovery medium, yielding over 50% cell survival and transfection rates above 30% for mouse and above 20% for human cells. The functional performance of the surviving cells was at least twice as high as with the original Lonza recovery medium.18PubMed Central. A solution for highly efficient electroporation of primary cytotoxic T lymphocytes
The electroporation buffer itself is another optimization lever. Research into the cGAS-STING toxicity pathway revealed that the osmotic pressure of the electroporation buffer can dampen cGAS-DNA interactions, reducing the cell’s inflammatory self-destruction response to cytoplasmic DNA. An isotonic buffer optimized for this purpose allowed production of CAR T cells with up to 20-fold higher cell numbers than standard electroporation conditions, and those CAR T cells showed higher anti-tumor activity in vivo than lentivirally generated counterparts.19PubMed. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway This is one of the more striking recent findings in the field: simply changing the salt composition of the buffer can turn a mediocre DNA electroporation protocol into one that rivals viral transduction.
Lipid Nanoparticle Delivery
Lipid nanoparticles (LNPs), made famous by mRNA COVID-19 vaccines, are being adapted for T cell transfection. The appeal is obvious: an off-the-shelf, scalable, potentially in vivo delivery vehicle that avoids the need for electroporation hardware. The challenge is that standard LNP formulations optimized for hepatocytes or muscle cells do not work well for T cells.
Recent optimization work has identified key compositional trends that improve LNP performance in primary human T cells: high cholesterol content and low polyethylene glycol (PEG) content both improve uptake and expression of mRNA cargo.20PubMed Central. Customizable mRNA Lipid Nanoparticles for Transfection of Primary Human T Cells A separate approach takes the concept further by designing “activating LNPs” that mimic antigen-presenting cells. These particles combine T cell activation (normally done with magnetic beads coated in stimulatory antibodies) and mRNA delivery in a single step. The resulting mRNA CAR T cells reduced tumor burden in a mouse model, suggesting this could simplify and speed up CAR T cell manufacturing.21PubMed Central. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy
Microfluidic Squeezing as an Alternative
Electroporation is not the only physical delivery method. Microfluidic cell squeezing forces cells through narrow constrictions that transiently disrupt the membrane, allowing cargo to diffuse in. A head-to-head comparison with electroporation found a dramatic difference in off-target cellular effects: electroporation caused about 17% of filtered genes to become misregulated, while cell squeezing caused essentially 0%. More importantly, T cells edited for PD-1 via electroporation failed to outperform untreated controls in a therapeutic tumor model, while T cells edited with similar efficiency via cell squeezing retained their expected tumor-killing advantage.22PubMed Central. Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo This is a sobering result for anyone relying on electroporation for therapeutic T cell products, and it highlights that transfection efficiency alone is not the right metric: you also need to ask whether your delivery method is undermining the function of the cells you are engineering.
Scaling Up for Clinical Manufacturing
Academic-scale electroporation typically handles thousands to a few million cells in a cuvette. Clinical manufacturing for a single patient dose of CAR T cells requires processing hundreds of millions to billions of cells. Standard cuvette-based systems suffer from low throughput, difficult optimization, and incompatibility with large-scale manufacturing.
Continuous-flow electroporation platforms address this by passing cells through a channel where they encounter the electric field in a steady stream rather than in static batches. One such system demonstrated over 95% transfection efficiency for mRNA delivery with less than 2% loss of viability compared to untreated control cells. By widening the flow channel from 2 mm to 10 mm, throughput scaled by a factor of five without any change in efficiency or viability, reaching an experimental throughput of 256 million cells per minute.23PubMed Central. Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing That kind of linear scalability, where you can increase production volume simply by widening the channel and increasing flow rate, is exactly what clinical manufacturing needs.
Genomic Safety Concerns with CRISPR Editing
One area where the field’s optimism deserves some tempering is genomic stability after Cas9 editing. Creating a double-strand break at a specific locus does not always resolve cleanly. Research has shown that chromosome loss is a general phenomenon in Cas9-edited T cells, regardless of which DNA repair pathway is involved, and that cells with chromosome loss are present among preclinical CAR T cell products.24Cell. Target-specific chromosome loss and p53-mediated responses following genome editing in human T cells
The numbers are not trivial. When Cas9 was targeted to the T cell receptor alpha locus on chromosome 14, up to 9% of cells lost that chromosome entirely four days after transfection, and about 1.4% gained an extra copy. Chromosome 7, which harbors the T cell receptor beta locus, was truncated in nearly 10% of cells. While most affected cells died or stopped dividing due to p53 activation, about 0.9% of T cells still carried a chromosome 14 loss 11 days after transfection.25Nature Biotechnology. Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage These findings do not mean CRISPR-edited T cell therapies are unsafe, but they do mean that monitoring for chromosomal abnormalities should be part of any clinical-grade manufacturing protocol. The p53 pathway appears to clear most aberrant cells naturally, but “most” is not “all,” and the residual population with aneuploidy deserves careful characterization before infusion into patients.